Compare · MITQ vs TMO
MITQ vs TMO
Side-by-side comparison of Moving iMage Technologies Inc. (MITQ) and Thermo Fisher Scientific Inc (TMO): market cap, price performance, sector, and recent activity on the wire.
Summary
- MITQ operates in Consumer Discretionary, while TMO operates in Industrials - the two are in different parts of the market.
- TMO is the larger of the two at $257.53B, about 47487.9x MITQ ($5.4M).
- TMO has been more active in the news (6 items in the past 4 weeks vs 4 for MITQ).
- TMO has more recent analyst coverage (25 ratings vs 0 for MITQ).
- Company
- Moving iMage Technologies Inc.
- Thermo Fisher Scientific Inc
- Price
- -
- -
- Market cap
- $5.4M
- $257.53B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Industrial Machinery/Components
- Industrial Machinery/Components
- Exchange
- AMEX
- NYSE
- IPO
- 2021
- News (4w)
- 4
- 6
- Recent ratings
- 0
- 25
Thermo Fisher Scientific Inc
Thermo Fisher Scientific Inc. offers life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and service worldwide. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets. Its Analytical Instruments segment provides instruments, consumables, software, and services for use in laboratory, on production line, and in field for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as clinical laboratories. The company's Specialty Diagnostics segment offers liquid, ready-to-use, and lyophilized immunodiagnostic reagent kits, as well as calibrators, controls, and calibration verification fluids; ImmunoCAP for allergy and asthma tests, and EliA for autoimmunity tests; dehydrated and prepared culture media, collection and transport systems, instrumentation, and consumables; human leukocyte antigen typing and testing for organ transplant market; and healthcare products. Its Laboratory Products and Services segment provides laboratory refrigerators and freezers, ultralow-temperature freezers, and cryopreservation storage tanks; temperature control, sample preparation and preservation, centrifugation, and biological safety cabinet products; water analysis instruments; laboratory plastics products; laboratory chemicals; and pharma services. The company offers products and services through a direct sales force, customer-service professionals, electronic commerce, third-party distributors, and catalogs. It has a strategic alliance with the University of California, San Francisco. The company was incorporated in 1956 and is based in Waltham, Massachusetts.
Latest MITQ
- Syufy Enterprises Selects Moving iMage Technologies For Turnkey Upgrade of 16 Screen Theater Complex in Mountain View, California
- Moving iMage Technologies Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits
- SEC Form 10-K filed by Moving iMage Technologies Inc.
- Cinema Solutions Provider Moving iMage Technologies Progresses Toward Profitability, Trimming FY 2026 Net Loss 69% to ($297K) on Net Sales of $17.3M; Hosts Investor Call Today at 11am ET
- Moving iMage Technologies Reschedules Q4 Call to Monday, September 28th at 11am ET
- SEC Form 4 filed by Chief Financial Officer Bedard Barton John
- SEC Form 3 filed by new insider Bedard Barton John
- Director Stiska John was granted 14,294 shares (SEC Form 4)
- Director Crothall Katherine D was granted 29,643 shares, increasing direct ownership by 107% to 57,357 units (SEC Form 4)
- Director Anderson Scott Lloyd was granted 38,039 shares, increasing direct ownership by 308% to 50,374 units (SEC Form 4)
Latest TMO
- SEC Form 4 filed by Director Weisler Dion J
- SEC Form 4 filed by Director Sperling Scott M
- SEC Form 4 filed by Director Lynch Karen S
- SEC Form 4 filed by Director Johnson Jennifer M
- SEC Form 4 filed by Director Keith R. Alexandra
- Thermo Fisher Scientific to Hold Earnings Conference Call on Wednesday, October 21, 2026
- Thermo Fisher Scientific Launches Gibco™ CHO-K1 Catalog Panel Media and Feed to Accelerate Biologics Development
- Thermo Fisher upgraded by UBS with a new price target
- CLSA initiated coverage on Thermo Fisher with a new price target
- Executive Vice President Shafer Michael D covered exercise/tax liability with 790 shares, decreasing direct ownership by 4% to 20,204 units (SEC Form 4)